University of Helsinki

50 face transplants in 11 countries show 85% 5-year and 74% 10-year survival rates, outperforming other transplants. Led by Dr. Pauliina Homsy, the study highlights successful outcomes and evolving techniques, though cost remains a barrier.

Torrey Pines Investment and Innovestor’s Life Science Fund, with Helsinki University Funds, launch Polku Therapeutics, a Helsinki-based startup developing novel drug treatments for neurodegenerative disorders, based on research by Professor Timo Myöhänen and Senior Scientist Erik Wallén at the University of Helsinki.

TILT Biotherapeutics presents Phase I data on TILT-123, an intravenous oncolytic adenovirus therapy for advanced solid cancers, at ESMO 2024, demonstrating safety and tumor transduction.